ATTENTION: Please enable Javascript in your browser for full site functionality.
Skip to navigation Skip to main content Skip to footer

Ticker Update

Updates

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall - Water for Injections BP – 100ml vial x 25

Hameln pharma ltd are recalling batches of product additional to the batch recalled on 15 February 2022 (reference EL(22)A/06). This recall is conducted as a precautionary measure, as remaining vials may no longer be in line with the licensed product specification with respect to the parameters pH and conductivity.

 

MHRA drug alert date: 25 May 2022

 

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-hameln-pharma-ltd-water-for-injections-bp-100ml-vial-el-22-a-slash-24?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=5178b109-19c7-4882-b7e7-ee9285e62098&utm_content=immediately

 

Pip code

Product description

Supplier

Batch Numbers

0769489

WATER FOR INJ BP VIAL R/C 100ML (25)

HAMELN PHARMACEUTICALS LTD (MOV)

019501

019502

019503

019504

019505

019506

920503

920506

920508

930503

930504

930505

931501

940501

940502

951504

952501

Further Information

 

For more information, medical or supply enquiries, please contact: drug.safety@hameln-pharma.co.uk

 

For stock control queries, please contact: customer.services@hameln-pharma.co.uk

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

 

Please note that anything not returned to us, or notified to us, within 3 months of this notification by the 26 August 2022, cannot be reimbursed by way of a credit

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall - Mefenamic Acid 500mg film coated, 30 tablets

Quadrant Pharmaceuticals Ltd are recalling a specific batch of Mefenamic Acid 500mg Film-Coated, 30 Tablets as a precautionary measure, due to observations of a defective layer of film coating in some tablets, resulting in the tablet core being partially exposed.

 

MHRA drug alert link:

https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-quadrant-pharmaceuticals-ltd-mefenamic-acid-500mg-film-coated-tablets-el-22-a-slash-23?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=bc363bcf-f3dc-4fbf-9017-327ecb34cd6f&utm_content=immediately

 

Pip code

Product Description

Supplier

Batch Numbers

ALLIANCE DO NOT STOCK

MEFENAMIC ACID 500MG FILM COATED, 30 TABLETS

QUADRANT PHARMACEUTICALS LTD

107082

Alliance do not stock the above product so we will not be accepting Customer returns on this recall.

 

Further Information

 

For more information, medical or supply enquiries, please contact joanne.fishwick@maxearn.co.uk or radoslaw.bandomir@maxearn.co.uk

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

SUB-TYPE:

13.05.2022

CARDENE order blackout period 17-18 May – LXO RWA

 

We are pleased to announce that, as of 19 May 2022, Alliance Healthcare UK will become the only wholesaler to supply CARDENE to all pharmacies, hospitals and dispensing doctors in England, Scotland and Wales. Northern Ireland is not included in this agreement. 


CARDENE has been acquired by Laboratoire XO from Astellas. Following the morning deliveries on Tuesday 17 May Astellas was cease Direct to Pharmacy sales for these products and there will be a transition to a Reduced Wholesaler Model with Laboratoire XO. As a result of this transition there will be a blackout period for customer orders of these products between 17 – 18 May.

 

Final orders for these products will be your standard cut-off time on the evening of Monday 16 May for AM delivery on the Tuesday 17 May. Customers will be able to place orders with Alliance Healthcare for these products from Thursday AM 19 May for delivery from PM 19 May.


From 19 May purchases of these lines will continue to arrive as part of your usual Alliance Healthcare delivery service and, if purchased in isolation, they will not be subject to Alliance Healthcare’s low spend surcharge. To receive these products, you can simply order from Alliance Healthcare in your usual manner. These products will be available on a same day delivery service.


If you would like to discuss these changes in more detail, please do not hesitate to contact your Alliance Healthcare Account Manager.

 

Please see these communications from Alliance Healthcare and Laboratoire XO for more information:

 

Alliance Healthcare - CARDENE customer communication

 

Laboratoire XO -  CARDENE customer communication

SUB-TYPE:

12.05.2022

Platinum Jubilee Service Information

 

To help keep our customers informed of changes to our service, we have published our Platinum Jubilee Bank Holiday opening hours. 

 

For more information please click here

SUB-TYPE:

11.05.2022

Alliance Healthcare marks £100k raised for Vitamin Angels UK

 

Alliance Healthcare marks £100,000 raised for Vitamin Angels UK to support its purpose in improving access to essential nutrition for mothers and children in the UK and around the world.


Yesterday, team members across Alliance Healthcare joined a virtual event called “Around the World” to celebrate the amazing £100,000 fundraising milestone. Marie Evans, Managing Director congratulated the teams who have completed cycle challenges, organised football matches and multiple fundraising events in aid of the charity.


Vitamin Angels UK provided an interactive virtual tour of the villages across the world where funds raised have helped create healthier futures. Over the last four years of the partnership, Alliance Healthcare and Vitamin Angels have reached the lives of over 468,600 children.


Sam Unsworth, CSR Champion for Alliance Healthcare closed the event and said: “We should be really proud of our fundraising efforts to support our charity partnership with Vitamin Angels. Today, was a moment to reflect on our achievement and hear more from the charity. This has really spurred us on to create even more impactful fundraising events. Together we will continue to make a meaningful difference for those that need it most.”

 

VA 6

VA3va1

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Drug Caution In Use - Zovirax I.V. 500mg

GlaxoSmithKline UK Ltd have informed the MHRA that an incorrect version of the Summary of Product Characteristics section 4.2 and the Patient Information Leaflet is inside the sealed pack, and contains unapproved text.

 

MHRA drug alert link:

https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-glaxosmithkline-uk-ltd-zovirax-iv-500-mg-el-22-a-slash-22?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=2fba3ba7-af6b-48f5-bcb3-903db16db3f2&utm_content=immediately

 

Pip code

Product description

Supplier

Batch Numbers

489633

ZOVIRAX IV VIAL 500MG

GLAXOSMITHKLINE UK LTD

9G4B

TC8E-A

6V8W

GN8S

J69C

B35J

This is a caution in use only we are not accepting stock returns.

 

Further Information

If you have any questions, please contact GSK UK Ltd Medical Information Department on 0800 221 441 or email: ukmedinfo@gsk.com

SUB-TYPE:

11.05.2022

Prince Charles praises pharmacy sector’s ‘dedication and professionalism’ during Covid-19 pandemic

 

Prince Charles has praised the “dedication and professionalism of pharmacy staff” at an event held in London to celebrate the work of community pharmacists during the Covid-19 pandemic.

His Royal Highness The Prince of Wales hosted a special event this week at St. James’s Palace State Apartments to celebrate Community Pharmacists.

200 community pharmacy members and other honoured guests, including Our Managing Director, Marie Evans had the privilege of attending.

Speaking about the event, Marie said: “Community pharmacy deserve this recognition, they continued to support UK patients at every moment of the pandemic – and beyond. Their unwavering dedication is something to be admired and celebrated. This has been a very fitting celebration for our remarkable community pharmacists and their teams.”

Read more about the event in the below link:

Prince Charles praises pharmacy sector’s ‘dedication and professionalism’ during Covid-19 pandemic - Latest Pharmacy News | Business | Magazine - Pharmacy Business

 

pc

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall - Accupro 5mg, 10mg, 20mg, 40mg film-coated tablets

Pfizer Limited are recalling all batches of Accupro 5mg, 10mg, 20mg, 40mg film-coated tablets as a precautionary measure.

 

MHRA drug alert link:

https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-pfizer-limited-accupro-5mg-10mg-20mg-40mg-film-coated-tablets-el-22-a-slash-21?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=c46b413b-c065-46f9-8947-94cdaeced6c0&utm_content=immediately

 

Pip code

Product description

Supplier

Batch Numbers

258764

ACCUPRO TAB 5MG X 28

PFIZER LTD

FJ7218

EY5501

EA9306

258780

ACCUPRO TAB 10MG X 28

PFIZER LTD

FK8588

EP6753

258822

ACCUPRO TAB 20MG X 28

PFIZER LTD

FF8046

FF8045

EA9304

DK4190

2035467

ACCUPRO TAB 40MG X 28

PFIZER LTD

FK9758

EP1602

CW7390

Further Information

 

For medical information enquiries, please contact Pfizer Medical Information Department on 01304 616161.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

 

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

SUB-TYPE:

05.05.2022

Alcura Rated “Good” in CQC Report

 

Alcura receive “Good” in its recent Care Quality Commission (CQC) report a high standard in a competitive market. “This accreditation will go a long way in demonstrating to our patients, future patients, the NHS and manufacturers, the high-level of patient care we deliver at Alcura. As a purpose led organisation, we are dedicated to patient care, so to receive this recognition for our safety is a fantastic reflection of our knowledge and expertise in homecare,” said Pip Reid, Head of Nursing, Alcura.

 

Alcura received the second highest possible score in its recent CQC report, following the recent unannounced inspection at Alcura House. CQC, the independent regulator of health and social care in England, completed an intense two-day inspection at the Alcura site in Northampton, in February, and recently published the report on its website.

 

Alcura was inspected as part of the Community Services pillar and its support to care in patient homes, where there is a big emphasis on safety.

 

The CQC Inspection Report is based on a combination of what the organisation finds when they undertake the inspection, the information from its ongoing monitoring of data about services and information handed by the provider, patients, the public and other organisation. The report covers five questions and areas within the services provided across: Safety, Effectiveness, Caring, Responsiveness and Leadership.

 

cq

 

CQC findings conclude that: “We rated the service as good because [..] The service had enough staff to care for patients and keep them safe. Alcura House had a pool of regular bank staff and did not use agency staff. Patients therefore received consistent care from the same nurses. All nursing staff had training in key clinical skills which had been tested through competency assessments.”

 

Other findings include: “Staff provide good care and treatment [..] Staff treated patients with compassion and kindness [..] Staff understood how to protect patients from abuse [..] Staff assessed risks to patients, acted on them and kept good care records.”

 

At the time of this inspection, Alcura had 1,252 clinical interactions per month and was supporting 45,000 registered patients. Alcura is committed to maintaining the high standards of patient safety and to identify and implement steps required to reach the highest CQC score - outstanding.

 

 

aw

 

 

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall - Sodium bicarbonate 1.26% Solution for infusion 500ml

Fresenius Kabi Limited are recalling the below batch of product as a precautionary measure due to the identification of particles in the solution for infusion, following routine batch analysis and subsequent batches manufactured on the same filling line. The company’s investigation indicates that he particles appear to originate from the interaction between the equipment and the packaging material during the filling process. The integrity of the packaging and sterility of the product are not compromised.

 

MHRA drug alert link:

https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-fresenius-kabi-limited-sodium-bicarbonate-1-dot-26-percent-solution-for-infusion-el-22-a-slash-20?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=ca886a23-3a40-4c69-811e-b116b6a59264&utm_content=immediately

 

Pip code

Product description

Supplier

Batch Number

ALLIANCE DO NOT STOCK

SODIUM BICARBONATE 1.26% SOLUTION FOR INFUSION 500ML

FRESENIUS KABI LIMITED

22BC01

Further Information

 

For more information, medical or supply enquiries, please contact 01928 533 758 FK.Complaints-UK@fresenius-Kabi.com or Customer.Services-UK@Fresenius-Kabi.com  

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.